Who is sponsoring NCT05296603?

NCT05296603 is sponsored by Hunan Province Tumor Hospital.

What drugs are being tested in NCT05296603?

Interventions in NCT05296603: IBI-322 Plus Lenvatinib.

What condition does NCT05296603 study?

NCT05296603 studies Small Cell Lung Cancer.

Is NCT05296603 still recruiting?

NCT05296603 is currently status unknown. Last updated 10 January 2024.

Last reviewed 2024-01-10 · How we verify

NCT05296603

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Status unknown Phase 2 Last updated 10 January 2024

What this trial tests

Phase 2 trial testing IBI-322 Plus Lenvatinib in Small Cell Lung Cancer in 83 participants. Status unknown.

Timeline

3 December 2021

Primary endpoint
30 October 2024

25 December 2025

Quick facts

Lead sponsor	Hunan Province Tumor Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	83
Start date	3 December 2021
Primary completion	30 October 2024
Estimated completion	25 December 2025
Sites	1 location across China

Drugs / interventions tested

IBI-322 Plus Lenvatinib — full drug profile →

Conditions studied

Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →

Sponsor

Hunan Province Tumor Hospital

Who can join

18 and older, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to explore the efficacy and biomarker explanation of IBI-322 Plus Lenvatinib on extensive stage small cell lung cancer who failed from first line PD-(L)1 inhibitors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska J, Shen J, Larionova I. · · 2024 · cited 79× · PMID 39516356 · DOI 10.1038/s41423-024-01232-z
Targeting macrophages: a novel treatment strategy in solid tumors.
Liu M, Liu L, Song Y, Li W, et al · · 2022 · cited 52× · PMID 36510315 · DOI 10.1186/s12967-022-03813-w
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.
Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, et al · · 2022 · cited 23× · PMID 35655707 · DOI 10.1080/2162402x.2022.2077898
Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer.
Luo X, Shen Y, Huang W, Bao Y, et al · · 2023 · cited 22× · PMID 36826231 · DOI 10.1177/10732748231159706
Targeting CD47 as a Novel Immunotherapy for Breast Cancer.
Chen C, Wang R, Chen X, Hou Y, et al · · 2022 · cited 17× · PMID 35860564 · DOI 10.3389/fonc.2022.924740
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors.
Gu Y, Zhao Q. · · 2024 · cited 16× · PMID 39172329 · DOI 10.1007/s40291-024-00734-w
Bispecific Antibodies in Solid Tumors: Advances and Challenges.
Shan KS, Musleh Ud Din S, Dalal S, Gonzalez T, et al · · 2025 · cited 12× · PMID 40565299 · DOI 10.3390/ijms26125838
Drug resistance mechanism and reversal strategy in lung cancer immunotherapy.
Xu Y, Liu Y, Ge Y, Li H, et al · · 2023 · cited 8× · PMID 37795038 · DOI 10.3389/fphar.2023.1230824

Verify or expand the search:

Other recruiting trials for Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Other Hunan Province Tumor Hospital trials

Trials by the same sponsor.

NCT06706219 — Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unres · Phase 2 · not yet recruiting
NCT07001995 — Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression · Phase 2 · not yet recruiting
NCT07477808 — Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07251582 — Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05296603 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hunan Province Tumor Hospital
Last refreshed: 10 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05296603.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing